Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, and advisor to MedTech suppliers reports on a new collaboration to use nuclear waste in cancer-fighting MedTech.
In a landmark move set to redefine cancer treatment, Bicycle Therapeutics has announced a 15-year agreement with the UK Nuclear Decommissioning Authority (NDA) to produce precision radiopharmaceuticals from hundreds of tonnes of reprocessed uranium. This pioneering collaboration promises tens of thousands of doses of cutting-edge therapies annually, targeting some of the most challenging cancers.
The partnership leverages a groundbreaking process developed by the UK National Nuclear Laboratory (UKNNL) to extract lead-212 – a highly valuable medical isotope – from reprocessed uranium. Through a complex series of steps, a minuscule amount of parent material is isolated, eventually yielding lead-212 for use in radiopharmaceuticals. These therapies deliver targeted radiotherapy directly to cancer cells, destroying tumours while minimizing side effects, a critical advantage for cancers resistant to conventional treatments, such as prostate and neuroendocrine cancers.
Under the agreement, Bicycle Therapeutics will access up to 400 tonnes of reprocessed uranium over 15 years, ensuring a sustainable supply of isotopes for precision oncology. The company, co-founded by Nobel laureate Sir Greg Winter, is at the forefront of developing Bicycle® molecules – a novel class of medicines for underserved diseases.
The UK Government has hailed the deal as a prime example of life sciences innovation driving both health and economic growth. Science and Technology Secretary Liz Kendall emphasized the transformative potential, saying: “Turning nuclear material into cutting-edge cancer treatments sounds like science fiction – but thanks to the brilliance of scientists, researchers and doctors, it could be a life-saving reality.”
This initiative complements recent government investments, including £20 million for lead-212 research and backing for major nuclear projects like Sizewell C and small modular reactors.
As government sees it, this collaboration represents more than innovation – it’s a blueprint for cross-industry partnerships that tackle healthcare’s toughest challenges. By turning nuclear by-products into life-saving treatments, the UK is positioning itself at the forefront of global oncology research and precision medicine.
The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
